WASHINGTON – The FDA's approval late Tuesday of Savient Pharmaceuticals Inc.'s Krystexxa (pegloticase), a pegylated uric acid specific enzyme for chronic refractory gout, "symbolizes what a small biotech can do," said President Paul Hamelin. (BioWorld Today) Read More
